(Q37319540)

19 August 2017

1 reference

title

New approaches to prediction of immune responses to therapeutic proteins during preclinical development (English)

1 reference

19 August 2017

Laura C A Perry

1

1 reference

19 August 2017

Timothy D Jones

series ordinal

2

1 reference

19 August 2017

Matthew P Baker

series ordinal

3

1 reference

19 August 2017

publication date

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

385-396

1 reference

Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F0126839-200809060-00004

The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0126839-200809060-00004

Rationally engineered therapeutic proteins with reduced immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0126839-200809060-00004

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F0126839-200809060-00004

10.2165/0126839-200809060-00004

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference